DEF 14A: Focus Universal Seeks Shareholder Approval for Increased Share Authorization, Board Member Elections, and Auditor Ratification

Sentiment:

Definitive Proxy Statement


Focus Universal is asking shareholders to vote on key proposals including electing board members, ratifying the auditor, and increasing the number of authorized shares at the upcoming annual meeting.

Capital raiseThe company is seeking to increase the number of authorized shares of common stock from 75,000,000 to 150,000,000.The company intends to use the additional authorized shares for future financing, acquisitions, and other general corporate purposes.The company is considering issuing part of the additional shares of Common Stock that will result from the adoption of the proposed amendment to raise funds as may be required from time to time to pursue our business objectives, including research and development of our products.

Summary

  • Focus Universal Inc. is holding its 2024 Annual Meeting of Shareholders on November 29, 2024, at its headquarters in Ontario, California.
  • Shareholders will vote on three key proposals: electing five members to the Board of Directors, ratifying the selection of Weinberg & Company, P.A. as the company's independent registered public accounting firm for the fiscal year ending December 31, 2023, and approving an amendment to the Articles of Incorporation to increase the number of authorized shares of common stock from 75,000,000 to 150,000,000.
  • The Board of Directors has fixed October 2, 2024, as the record date for determining shareholders entitled to vote at the Annual Meeting.
  • As of September 30, 2024, there were approximately 68,667,760 shares of Common Stock issued and outstanding.
  • The Board of Directors recommends voting for all director nominees, ratifying the auditor, and approving the increase in authorized shares.

Sentiment

Score: 6

Explanation: The document is a standard proxy statement, presenting routine matters for shareholder vote. While the increase in authorized shares could be seen as a positive for future growth, it also carries the risk of dilution. The sentiment is neutral to slightly positive.

Positives

  • The proposed increase in authorized shares provides the company with greater flexibility for future financing and strategic transactions.
  • The Board of Directors is composed of a majority of independent directors, ensuring strong corporate governance.
  • The company has established Audit, Compensation, and Nominating and Corporate Governance Committees to oversee key areas of corporate governance.

Negatives

  • The increase in authorized shares could potentially dilute existing shareholders' ownership if new shares are issued.
  • The company has engaged in related party transactions, including loans from the CEO and shareholders, which could raise concerns about conflicts of interest.
  • Two of the five board members are not independent.

Risks

  • Failure to obtain shareholder approval for the proposed increase in authorized shares could limit the company's ability to raise capital and pursue strategic opportunities.
  • Issuance of additional shares could dilute existing shareholders' ownership and voting rights.
  • Related party transactions could create potential conflicts of interest and may not be on terms as favorable as those available from unrelated parties.

Future Outlook

The company intends to use the additional authorized shares for future financing, acquisitions, and other general corporate purposes, but has no definitive plans at this time.

Management Comments

  • The Board believes that additional authorized shares of Common Stock will enable us to take timely advantage of market conditions and favorable financing and acquisition opportunities that become available to us.

Industry Context

Many companies seek to increase their authorized share capital to provide flexibility for future growth and strategic initiatives. This proposal aligns with common corporate practices.

Comparison to Industry Standards

  • The document mentions a survey of shares of Common Stock authorized and shares of Common Stock outstanding at our peer group companies, to strike the appropriate balance so that we do not have what some shareholders might view as an unreasonably high number of authorized shares of Common Stock that are unissued or reserved for issuance.
  • However, the document does not list any specific comparable companies, projects, or results.

Related Party Transactions

  • Revenue generated from Vitashower Corp., a company owned by the Chief Executive Officer's wife, amounted to $0 and $41,536 for the years ended December 31, 2023 and 2022, respectively.
  • Service revenue generated from the installation of home security equipment by AT Tech and AVX for one of the Company's directors amounted to $65,543 and $8,246 for the years ended December 31, 2023 and 2022, respectively.
  • On September 7, 2023, the Company entered into a loan agreement with Golden Sunrise Investment LLC in the amount of $1,000,000.
  • On April 2, 2024, the Company entered into a two-year loan agreement with the Company's CEO Desheng Wang for the amount of $300,000.

Stakeholder Impact

  • Approval of the increase in authorized shares could impact shareholders through potential dilution.
  • The election of directors will determine the leadership and strategic direction of the company, impacting all stakeholders.
  • The ratification of the auditor ensures the integrity of the company's financial reporting, benefiting shareholders and creditors.

Next Steps

  • Shareholders will vote on the proposals at the Annual Meeting on November 29, 2024.
  • The Board will determine whether to file the Certificate of Amendment with the Secretary of State of the State of Nevada if shareholders approve the proposal.

Key Dates

DateDescription
December 29, 2014Dr. Desheng Wang appointed as Chief Executive Officer, Secretary, and director of the Company
October 21, 2015Dr. Edward Lee appointed President and director of the Company
June 8, 2018Michael Pope and Carine Clark appointed as independent directors of the Company
December 17, 2018The Company adopted the 2018 Stock Option Plan
November 15, 2019Dr. Lee resigned as President and was appointed as Chairman of the Board
November 3, 2021Employment agreement date for Irving Kau for the provision of services as VP of Finance
November 10, 2021Irving Kau served as Focus Universals Vice President of Finance and Head of Investor Relations
August 10, 2022Sean Warren was appointed as an independent director of the Company
November 18, 2022Irving Kau was appointed as Chief Financial Officer of the Company
September 7, 2023The Company entered into a loan agreement with Golden Sunrise Investment LLC in the amount of $1,000,000
January 5, 2024Weinberg & Company, P.A. was appointed to serve as our independent registered public accounting firm for the fiscal year ending December 31, 2023
January 16, 2024The Company filed a Current Report on Form 8-K with the SEC announcing the change in auditors
March 5, 2024The Company entered into an addendum to the loan agreement with Golden Sunrise Investment LLC, a related party obtaining an additional secured loan amount of $300,000
April 2, 2024The Company entered into a two-year loan agreement with the Companys CEO Desheng Wang for the amount of $300,000
July 3, 2024The principal and interest were paid off on the loan with Golden Sunrise Investment LLC
July 9, 2024The principal and interest were paid off on the loan with the Companys CEO Desheng Wang
September 18, 2024Due to the purchase of PIPE shares, Dr. Wang has 22,729,550 shares and Dr. Lee has 12,022,500 shares
September 27, 2024The Board determined by written consent to approve the Certificate of Amendment, subject to shareholder approval and the Boards discretion to effect the Certificate of Amendment, to authorize an additional 75 million shares of Common Stock
October 1, 2024Date of the Proxy Statement
October 2, 2024Record Date for determining shareholders entitled to notice of and to vote at the Annual Meeting
November 29, 2024Date of the 2024 Annual Meeting of Shareholders
December 31, 2024Deadline for shareholders to submit proposals for the 2025 Annual Meeting of Shareholders
April 1, 2026Due date of the principal and interest amount for the loan agreement with the Companys CEO Desheng Wang

Keywords

Annual Meeting, Proxy Statement, Shareholders, Board of Directors, Authorized Shares, Common Stock, Weinberg & Company, Auditor Ratification, Director Election, Corporate Governance

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.